DHTKD1 and neoplasm: Oncolytic adenoviral expressing E1A, as monotherapy, is effective against tumor cell lines and xenograft tumor models (Yu et al., 1999; Hoti et al., 2007; Itamochi et al., 2007; Rojas et al., 2010), but only marginal benefit has been seen to date in clinical trials (Chiocca et al.,2004; Small et al.,2006).